FEIM — Fiscal Q1 2027 (Quarter Ended July 31, 2026) Financial Report Analysis

Revenue up 70%, and almost all of it dropped to the bottom line

Frequency Electronics makes precision timing and frequency-control hardware — atomic clocks, oscillators and GPS-based timing systems — mostly for communication satellites and U.S. defense programs. In the quarter ended July 31, 2026 (the company's fiscal first quarter of FY2027; its fiscal year ends April 30, so this is not a calendar quarter), revenue rose 69.8% to $23.5 million while operating income went from $0.4 million to $5.2 million. The company also raised roughly $58 million in a stock offering that closed one day before the quarter ended, taking cash from $1.6 million to $61.4 million.

Two things happened at once: the company shipped much more, and it earned more on each dollar shipped. Gross margin — the share of revenue left after the direct cost of building the product, before overhead, R&D and tax — went from 36.8% to 45.8%. Management attributes the 9-point gain "in part to product mix with the majority of programs running at targeted margins, and partially due to efficiencies recognized as programs mature."

Source: condensed consolidated statements of operations and Note G (segment information), Form 10-Q for the quarterly period ended July 31, 2026, filed September 14, 2026.

What actually drove the revenue increase

Growth was broad rather than concentrated in one program. By end market, satellite work — commercial and U.S. Government communication satellite programs — grew $5.3 million (+80.8%) and non-space U.S. Government/Department of War work grew $4.2 million (+61.3%). Satellite moved from about 47% of revenue to about 50%; non-space government slipped from about 50% to about 47%, not because it shrank but because satellite grew faster. Other commercial and industrial work stayed at about 3% of the total.

By operating segment, both units grew and both got more profitable:

FEI-NY, the larger unit, produced $4.1 million of the $4.8 million increase in operating income on a 69.9% revenue gain. FEI-Zyfer grew faster in percentage terms (+87.1%) but from a much smaller base, and its cost of revenues grew faster than its sales ($2.09M to $4.67M, +123%), so its margin expansion was more modest.

Almost all of this revenue is recognized "over time" using percentage-of-completion accounting — revenue is booked as costs are incurred against a contract's total estimated cost, rather than when a box ships. Of the $23.45 million, $22.42 million came in that way, versus $12.43 million of the year-ago $13.81 million. The point-in-time (shipped-and-titled) portion actually shrank, from $1.38 million to $1.03 million. That matters for interpreting the margin gain: under percentage-of-completion, when a program's estimated lifetime margin is revised upward, the catch-up flows through revenue in that period. The filing does not disclose a specific favorable estimate revision, but the accounting means "program maturity" improvements show up immediately rather than gradually.

Operating leverage was the story below the gross margin line

Revenue rose 69.8% while selling, general and administrative expense rose only 14.5% ($3.59M to $4.11M), falling from 26.0% of revenue to 17.5%. Management says the increase "related mostly to compensation expenses" — total stock-based compensation charged to equity roughly doubled, from $0.37 million to $0.73 million. R&D rose 27.5% to $1.45 million, a real increase but still well below the revenue growth rate, and its mix shifted sharply toward FEI-NY ($0.55M to $1.13M) while FEI-Zyfer's R&D fell ($0.58M to $0.32M).

The result: $9.6 million of additional revenue produced $4.8 million of additional operating income — an incremental operating margin of about 50%, which is what happens when a fixed-cost manufacturing base absorbs a large volume increase and the margin rate rises at the same time.

The parts of the profit that won't repeat at this rate

Two line items below operating income flatter the headline EPS, and both are worth separating out.

Tax. The quarter carried an effective tax rate of 19.58%, helped by a $0.3 million discrete benefit "primarily due to stock compensation windfall deductions" — the extra deduction a company gets when employees' shares vest at a price above the value originally expensed. The company's own estimate of the full-year FY2027 effective rate is 24.90%. Applying that rate to the quarter's $5.24 million of pre-tax income would have produced about $3.94 million of net income and roughly $0.38 of EPS instead of $0.41. The prior-year comparison is distorted in the opposite direction: Q1 FY2026 recorded a tax benefit of 13.89%, which is why net income grew 565% while pre-tax income grew 841%.

Share count. The July 30, 2026 offering closed one day before the quarter ended, so essentially none of the 1,086,957 newly issued company shares are in the 10.23 million weighted average used for the $0.41 EPS. Shares outstanding were 10.96 million at July 31, and the underwriters exercised their over-allotment option in full on August 3, buying another 260,869 shares — about 11.22 million shares outstanding going into the second quarter, roughly 10% above the weighted average that produced this quarter's EPS. Identical dollar earnings on the post-offering count would be about $0.38 per share. Stack the two effects together and the "clean" run-rate EPS for this quarter's level of profit is closer to $0.35 than $0.41.

Neither adjustment changes the operating story. They change what the reported EPS implies about the next few quarters.

Backlog and what it does and doesn't cover

Funded backlog — signed, funded work not yet recognized as revenue, excluding unfunded portions of fixed-price contracts and anything without authorization to proceed — was approximately $129 million at July 31, 2026, up from approximately $111 million at April 30, 2026.

The filing does not give a year-ago backlog figure, so the meaningful comparison is the three-month move. Backlog grew $18 million while the company recognized $23.5 million of revenue out of it, implying roughly $41 million of funded orders added in the quarter — a book-to-bill of about 1.8x. Treat that as an approximation rather than a bookings disclosure: funded backlog also rises when previously unfunded portions of existing contracts receive funding, which the company explicitly flags as a source of additions.

The more useful test is coverage. About 67% of $129 million, or roughly $86 million, is expected to convert to revenue within twelve months. Annualizing this quarter's $23.5 million gives a $94 million run rate. So the funded book scheduled for the next year covers roughly 90% of the current revenue pace — enough to make a sharp near-term decline unlikely, not enough by itself to fund continued growth without further orders. The company states plainly that backlog "is not necessarily indicative of future revenues or profits."

Takeaway: The 9-point gross margin gain, not the 70% revenue increase, is what makes this quarter hard to dismiss — volume growth alone would have produced a fraction of the $4.8 million operating income swing. The open question is durability: under percentage-of-completion accounting, "programs running at targeted margins" is a statement about estimates that can be revised in either direction, and the filing gives no way to separate a structurally better cost base from a favorable point in several programs' lifecycles.

Balance sheet: from thin to over-capitalized in one quarter

Cash went from $1.6 million at April 30 to $61.4 million at July 31, entirely from the equity raise. The company sold 1,086,957 shares at $57.50 (selling stockholders sold a further 652,174 shares, from which the company received nothing), grossing about $62.5 million and netting about $58.1 million after $3.8 million of underwriting discounts and $0.6 million of expenses. The August over-allotment added about $14.1 million net, which lands in fiscal Q2. Total net proceeds are therefore roughly $72 million.

Working capital rose from $27.0 million to $90.2 million and the current ratio from 2.3x to 5.3x. Total stockholders' equity more than doubled, from $56.4 million to $119.8 million. Separately, on June 12, 2026 the company signed a three-year $10.0 million senior secured revolving credit facility with JPMorgan Chase, undrawn at quarter end, with an option to upsize by a further $10.0 million and a 0.35% commitment fee on the undrawn balance. The company was in compliance with all covenants.

Stated use of proceeds is "general corporate purposes and investments in the Company's future growth" — deliberately non-specific. The filing does mention the company "may also pursue acquisitions to expand its range of products." For context on the scale: $61.4 million of the $153.6 million total asset base now sits at the corporate level as cash, against a business whose annualized revenue is roughly $94 million and whose quarterly capital spending is under $1 million ($0.84 million this quarter). This is a lot of idle capital relative to the operating footprint, and one consequence is already visible — investment income fell from $218 thousand to $61 thousand year over year, because the cash only arrived at the very end of the quarter and contributed almost nothing to interest income.

Cash generation lagged earnings, as expected. Operating cash flow was $2.6 million against $4.2 million of net income, because working capital absorbed $4.1 million. Contract assets — work performed but not yet billable — rose $2.4 million to $19.6 million and receivables rose $1.6 million to $6.2 million, partly offset by a $2.1 million increase in contract liabilities (customer advances) to $11.5 million. That pattern is normal for a percentage-of-completion business growing this fast: revenue is recognized before the milestone billing catches up. It is worth watching only if contract assets keep outgrowing revenue over several quarters. Inventories actually fell slightly, from $22.6 million to $22.2 million, with work-in-progress down $1.5 million — consistent with converting existing WIP into revenue rather than building stock ahead of demand.

The $20.0 million share repurchase authorization was untouched this quarter ($19.0 million remains). Buying back stock in the same quarter as a $57.50 equity offering would have been contradictory; the prior-year quarter, by contrast, saw 21,910 shares repurchased at an average $26.60.

Forward view

The company gives no revenue or earnings guidance in this 10-Q. The forward-looking figures it does provide are narrow and specific: an estimated 24.90% effective tax rate for fiscal 2027, approximately 67% of the $129 million funded backlog converting within twelve months, and a statement that liquidity is adequate through at least September 14, 2027.

What to watch, in rough order of importance:

1. Whether the 45.8% gross margin rate holds. Nine points of rate improvement in a single year is large for a contract manufacturer, and the stated causes — mix and program maturity — are both reversible. A single quarter at this level is not yet a trend line.
2. Whether bookings keep pace. Funded backlog covering about 90% of the annualized revenue run rate is adequate, not comfortable. If backlog stops growing while revenue runs at $23 million a quarter, the coverage ratio deteriorates quickly.
3. What the $72 million gets spent on. The filing points at acquisitions and "investments in future growth" without committing to either. Until deployed, the cash earns interest and dilutes return on equity; deployed badly, it does worse. The company's historical capital intensity is low, so this is not obviously an organic-capacity problem the cash solves.
4. EPS optics in Q2 FY2027. The next quarter carries roughly 10% more shares and a higher tax rate, and it gets a full quarter of interest income on about $75 million of cash. The first two work against reported EPS and the third for it; a flat sequential EPS print would still be consistent with flat or slightly better operating performance.

The reasonable read on trajectory: the operating business is genuinely performing better than it was a year ago, on both volume and margin, and the balance sheet risk that would normally accompany a small defense supplier scaling up has been removed outright. The unresolved question is whether fiscal Q1's margin rate is the new baseline or the top of a range — and one quarter of percentage-of-completion accounting is not enough to answer it.